We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with type 2 diabetes did not have higher risk for ...

In patients with type 2 diabetes (T2D) and metabolic dysfunction–associated steatotic liver disease (MASLD), the risk for major liver outcomes appears similar with dipeptidyl peptidase 4 (DPP-4) and ...

A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor. Results: Initially, more than 50% of ...

Among older veterans with type 2 diabetes (T2D), the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors as an add-on therapy is associated with a higher risk for peripheral artery disease ...

NEW YORK (Reuters) - GlaxoSmithKline Plc will study combining its diabetes drug Avandia with a new class of DPP-4 medicines but does not believe its established drug is under threat, its chief ...

Real-world study in type 2 diabetes suggests possible association, but more research is ne ...

For patients with diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) don’t appear to increase suicidality over what’s seen with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or ...

AMSTERDAM (Reuters) - Diabetes pills known as DPP-4 therapies got a mixed safety report on Monday as studies showed they did not raise the risk of heart attacks but might be linked to heart failure, ...